Related Experiment Video

Updated: May 22, 2026

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
07:25

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

Update on clinical trials evaluating the effect of biologic therapy in patients with critical limb ischemia

Richard J Powell1

  • 1Section of Vascular Surgery, Dartmouth-Hitchcock Lebanon Medical Center, Lebanon, NH 03756-0001, USA. Richard.Powell@hitchcock.org

Journal of Vascular Surgery
|May 29, 2012
PubMed

Insights

Biologic therapies like gene and cellular therapy show promise for treating critical limb ischemia (CLI) in patients with no revascularization options. These advanced treatments aim to improve wound healing and prevent amputation, with ongoing phase 3 trials evaluating their efficacy.

Area of Science:

  • Regenerative Medicine
  • Vascular Surgery
  • Biotechnology

Background:

  • Critical limb ischemia (CLI) is a severe form of peripheral arterial disease.
  • CLI significantly increases morbidity, mortality, and amputation rates.
  • Up to 40% of CLI patients without revascularization options require amputation within a year.

Purpose of the Study:

  • To review recent advancements in biologic therapies for CLI.
  • To summarize findings from gene and cellular therapy clinical trials in CLI patients.
  • To outline future directions for these innovative treatments.

Main Methods:

  • Analysis of recent phase 2 clinical trial data for gene and cellular therapies.
  • Review of safety and preliminary efficacy outcomes.
  • Discussion of ongoing phase 3 trial designs and objectives.

Main Results:

  • Phase 2 trials indicate acceptable safety profiles for biologic therapies.
  • Evidence suggests potential for improved wound healing and limb salvage.
  • These therapies offer hope for "no-option" CLI patients.

Conclusions:

  • Gene and cellular therapies represent a promising frontier for managing CLI.
  • Further investigation in phase 3 trials is crucial to confirm efficacy.
  • Biologic treatments may reduce amputation rates in high-risk CLI populations.

More Related Videos

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia07:48

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity09:38

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Published on: January 31, 2025

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...